Response Prediction in EBV-HLH Using Metabonomics Analysis

Capital Medical University

Status: Not yet enrolling

Conditions: EBV; Hemophagocytic Lymphohistiocytoses; Metabonomics

Treatments: Other: observational

Study type: Observational

Funder types: Other

Identifiers

NCT05677178

2022-P2-092-01

Details and patient eligibility

About

Hemophagocytic lymphohistiocytosis (HLH) is a rare, poorly recognized and underdiagnosed syndrome of excessive immune activation, which is rapidly fatal. Epstein-Barr virus (EBV) is a common trigger of HLH, particularly in Asian individuals. We aim to analyze metabolomics and cytokine profiles of patients before and after treatment to explore the metabolomic characteristics of EBV-HLH, and search for pathogenic mechanisms and therapeutic targets.

Full description

Hemophagocytic lymphohistiocytosis (HLH) is a rare, poorly recognized and underdiagnosed syndrome of excessive immune activation, which is rapidly fatal. Without early intervention, the median survival time is less than 2 months.Epstein-Barr virus (EBV) is a common trigger of HLH, particularly in Asian individuals. We aim to analyze metabolomics and cytokine profiles of patients before and after treatment to explore the metabolomic characteristics of EBV-HLH, and search for pathogenic mechanisms and therapeutic targets.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who meet HLH-04 diagnostic criteria
• EBV-DNA viral load in the peripheral blood > 500 copies/mL
• Informed consent obtained.

Exclusion criteria

• refuse to participate.

Trial design

30 participants in 2 patient groups

survival group

Description:

Patients who survived 2 months after treatment.

Treatment:

Other: observational

death group

Description:

Patients who died 2 months after treatment.

Treatment:

Other: observational